ライフサイエンスコーパス: midodrine

1 , discontinuation, or follow-up of new start midodrine.

2 hypotension may respond to erythropoietin or midodrine.

3 f placebo, the alpha1-adrenoreceptor agonist midodrine (5 to 10 mg), the alpha2-adrenoreceptor agonis

4 those discharged from the ICU or hospital on midodrine, 50% were concomitantly prescribed antihyperte

5 e randomized to receive a nonpressor dose of midodrine (5mg) or placebo on day 1 and the opposite on

6 ossover trial to investigate the efficacy of midodrine, a selective alpha-1 adrenergic agonist that d

7 with albumin (TERLI group) and 22 to receive midodrine and octreotide plus albumin (MID/OCT group).

8 albumin is significantly more effective than midodrine and octreotide plus albumin in improving renal

9 tiveness of terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment o

10 n is not available, as in the United States, midodrine and octreotide with albumin are used as an alt

11 The efficacy of Midodrine and Serotonin Uptake Inhibitors is currently u

12 period, 1,010 patients were newly started on midodrine and survived to ICU discharge.

13 -up tilt were significantly different on the midodrine and the placebo day: on the placebo day, 67% (

14 03 (2), ST-1059 (3, the active metabolite of midodrine), and phenylpropanolamine (4).

15 The combination of octreotide, midodrine, and albumin (triple therapy) is used to treat

16 available and generally fludrocortisone and midodrine are the drugs of first choice.

17 reflect underlying conditions, the need for midodrine before kidney transplantation is a risk marker

18 istory of congestive heart failure predicted midodrine continuation at hospital discharge (odds ratio

19 d medical/surgical ICU was a risk factor for midodrine continuation at ICU discharge (odds ratio, 3.9

20 This study established a high prevalence of midodrine continuation in transitions of care.

21 s developed neurally mediated syncope on the midodrine day (p < 0.02).

22 Midodrine decreased both supine and upright HR (all HR v

23 ine to 99+/-2 mm Hg at 2 hours, P<.001), and midodrine decreased supine systolic BP mildly.

24 or factors, as well as for the propensity of midodrine exposure, pretransplant midodrine use was inde

25 ogistic regression, including propensity for midodrine exposure.

26 concomitant vasoactive medications (3 in the midodrine group, 6 in the placebo group).

27 st, patients discharged from the hospital on midodrine had a higher risk of 1-year mortality (hazard

28 Midodrine hydrochloride, an alpha-agonist, could improve

29 Midodrine is an alpha1-agonist approved for orthostatic

30 Midodrine is efficacious and safe in the treatment of ne

31 Midodrine is prescribed to prevent symptomatic hypotensi

32 Adjunctive midodrine may decrease ICU length of stay (LOS) and ther

33 Adjunctive midodrine may decrease ICU LOS, duration of IV vasopress

34 Midodrine may decrease IV vasopressor support duration,

35 Midodrine may increase risk of bradycardia.

36 While midodrine may provide benefit for patient-centered outco

37 The effect of midodrine+octreotide (67.8 reversals per 1,000 [95% CI,

38 be more appropriate than initial trial with midodrine+octreotide.

39 cy of active vasoactive drugs (terlipressin, midodrine, octreotide, noradrenaline, and dopamine; alon

40 ome; albumin; vasoconstrictor; terlipressin; midodrine; octreotide; noradrenaline; and norepinephrine

41 Finally, vasoconstrictor agents such as midodrine offer promise and remain the subject of clinic

42 They were randomized to a 10-mg dose of midodrine or placebo 3 times per day in a 6-week study,

43 The MID/OCT group received midodrine orally at an initial dose of 7.5 mg thrice dai

44 ine over placebo (4.17, 1.37-12.50) and over midodrine plus octreotide (10.00, 1.49-50.00) for this o

45 dence supported the use of terlipressin over midodrine plus octreotide (OR 26.25, 95% CI 3.07-224.21)

46 adrenaline with albumin are both superior to midodrine plus octreotide with albumin for reversal of h

47 evidence supported the use of noradrenaline, midodrine plus octreotide, and dopamine plus furosemide

48 ion were associated with a decreased odds of midodrine prescription at both ICU and hospital discharg

49 2006 to 2008, of whom 308 (1.9%) had filled midodrine prescriptions in the year before transplantati

50 At 3 months, patients who used midodrine pretransplant had significantly (P < 0.05) hig

51 In the supine position, midodrine produced no significant change in blood pressu

52 In the evaluable patients, midodrine resulted in improvements in standing systolic

53 inephrine, and combination of octreotide and midodrine) should be used in the treatment of HRS-AKI, b

54 These results indicate that midodrine significantly improves orthostatic tolerance d

55 (1) and ST-1059 (2, the active metabolite of midodrine), supporting the hypothesis that greater alpha

56 e response of patients to the alpha1-agonist midodrine supports the hypothesis of partial dysautonomi

57 with the selective alpha1-adrenergic agonist midodrine, the inappropriate heat loss over their tail s

58 were performed in the ICU, 3) evaluated oral midodrine therapy compared with placebo or usual care, a

59 34% (311/909) of patients were continued on midodrine therapy.

60 incidence of continuation of newly initiated midodrine upon ICU and hospital discharge and identify r

61 We hypothesized that midodrine use before kidney transplantation may be a nov

62 pensity of midodrine exposure, pretransplant midodrine use was independently associated with risks of

63 Adjusted associations of pretransplant midodrine use with complications at 3 and 12 months post

64 Safety of midodrine was assessed as a secondary outcome.

65 Discharge from the ICU on midodrine was associated with a significantly shorter IC

66 Midodrine was continued in 67% (672/1,010) of patients a